A high-throughput electron tomography workflow reveals over-elongated centrioles in relapsed/refractory multiple myeloma.
bone marrow
centriole fragmentation
centriole over-elongation
centrosome
electron tomography
high-throughput electron microscopy
multiple myeloma
plasma cell disorder
Journal
Cell reports methods
ISSN: 2667-2375
Titre abrégé: Cell Rep Methods
Pays: United States
ID NLM: 9918227360606676
Informations de publication
Date de publication:
21 11 2022
21 11 2022
Historique:
received:
08
04
2022
revised:
24
08
2022
accepted:
06
10
2022
entrez:
1
12
2022
pubmed:
2
12
2022
medline:
2
12
2022
Statut:
epublish
Résumé
Electron microscopy is the gold standard to characterize centrosomal ultrastructure. However, production of significant morphometrical data is highly limited by acquisition time. We therefore developed a generalizable, semi-automated high-throughput electron tomography strategy to study centrosome aberrations in sparse patient-derived cancer cells at nanoscale. As proof of principle, we present electron tomography data on 455 centrioles of CD138
Identifiants
pubmed: 36452870
doi: 10.1016/j.crmeth.2022.100322
pii: S2667-2375(22)00212-0
pmc: PMC9701608
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
100322Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
H.G. has research funding from Amgen, BMS, Celgene, Chugai, Janssen, Incyte, Molecular Partners, Merck Sharp and Dohme, Sanofi, Mundipharma GmbH, Takeda, Dietmar-Hopp-Foundation, Johns Hopkins University, and Novartis; served as an advisor for Adaptive Biotechnology, Amgen, BMS, Celgene, Janssen, Sanofi, and Takeda; and received honoraria from Amgen, BMS, Celgene, Chugai, GlaxoSmithKline, Janssen, Novartis, and Sanofi. C.M.-T. served as a consultant for Janssen and received research funding from Bioline, Pfizer, and Janssen. M.S.R. received research funding from Amgen, Sanofi, Novartis, and Heidelberg Pharma and served as a consultant for Amgen, Sanofi, Novartis, BMS, Janssen, AbbVie, Regeneron, Takeda, and GSK. U.H. received travel grants from Janssen, Prothena, and Pfizer; served on advisory boards for Pfizer, Janssen, and Prothena; received honoraria from Janssen, Pfizer, Alnylam, and Akcea; and received research funding from Janssen and Prothena. A.K. received honoraria from Hoffmann-La Roche, Bayer, Daiichi Sankyo, and AbbVie and research funding from Bayer and Merck and is a paid consultant for Hoffmann-La Roche, Daiichi Sankyo, Bristol Myers Squibb, and AbbVie.
Références
Blood. 2008 Feb 1;111(3):1603-9
pubmed: 18006703
Curr Opin Struct Biol. 2021 Feb;66:89-95
pubmed: 33220554
Nat Methods. 2019 Jun;16(6):471-477
pubmed: 31086343
Cancer Res. 2016 Nov 15;76(22):6690-6700
pubmed: 27634760
Nat Rev Mol Cell Biol. 2007 Jun;8(6):451-63
pubmed: 17505520
J Cell Biol. 2020 Jun 1;219(6):
pubmed: 32271878
Immunity. 2015 Jul 21;43(1):132-45
pubmed: 26187412
J Microsc. 2019 Dec;276(3):145-159
pubmed: 31691972
Haematologica. 2021 Oct 01;106(10):2754-2758
pubmed: 34092058
Nat Cell Biol. 2019 Jan;21(1):72-84
pubmed: 30602772
Nat Rev Mol Cell Biol. 2018 May;19(5):297-312
pubmed: 29363672
Leukemia. 2003 Nov;17(11):2207-13
pubmed: 14523473
Nat Rev Cancer. 2015 Nov;15(11):639-52
pubmed: 26493645
Nature. 2009 Jul 9;460(7252):278-82
pubmed: 19506557
J Struct Biol. 2017 Feb;197(2):102-113
pubmed: 27444392
Cell Host Microbe. 2020 Dec 9;28(6):853-866.e5
pubmed: 33245857
Open Biol. 2021 Feb;11(2):200399
pubmed: 33561384
J Cell Biol. 2022 May 2;221(5):
pubmed: 35404385
Nat Commun. 2019 Aug 23;10(1):3835
pubmed: 31444325
Nat Methods. 2019 Jan;16(1):71-74
pubmed: 30559430
Cancer Res. 2005 Feb 1;65(3):850-60
pubmed: 15705883
Nat Commun. 2019 Mar 1;10(1):993
pubmed: 30824690
Curr Biol. 2009 Jun 23;19(12):1012-8
pubmed: 19481460
Curr Biol. 2021 Oct 11;31(19):4340-4353.e7
pubmed: 34433076
Nat Methods. 2016 May;13(5):387-8
pubmed: 27067018
J Struct Biol. 2005 Oct;152(1):36-51
pubmed: 16182563
Cell. 2021 Sep 2;184(18):4819-4837.e22
pubmed: 34380046
Nat Commun. 2018 Mar 28;9(1):1258
pubmed: 29593297
Blood Adv. 2017 Feb 14;1(6):407-416
pubmed: 29296956
Elife. 2020 Apr 03;9:
pubmed: 32242819
Nat Cell Biol. 2005 Nov;7(11):1140-6
pubmed: 16244668
J Struct Biol. 1992 Jul-Aug;109(1):1-12
pubmed: 1286005
Blood. 2012 Aug 2;120(5):1087-94
pubmed: 22705595
J Struct Biol. 1997 Nov;120(2):117-33
pubmed: 9417977
J Cell Biol. 2018 Jul 2;217(7):2353-2363
pubmed: 29739803
Cell Rep. 2017 Aug 22;20(8):1906-1920
pubmed: 28834753
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Nat Rev Clin Oncol. 2017 Feb;14(2):100-113
pubmed: 27531699
J Struct Biol. 1996 Jan-Feb;116(1):71-6
pubmed: 8742726